Currently 6 million Americans have Alzheimer's, and that could triple by 2050. However, the emergence of new drugs that can slow cognitive decline are offering hope to millions. Leal Therapeutics' Asa Abeliovich recently joined the Unseen Upside podcast by Cambridge Associates to discuss the future of Alzheimer’s treatment, how these new therapeutics work, and why Leal is so passionate about making an impact in this space. Listen here: https://ow.ly/2ION50QCpug #UnseenUpside
About us
Developing novel therapeutics for patients with major disorders of the central nervous system
- Website
-
https://lealtx.com/
External link for Leal Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at Leal Therapeutics
Updates
-
We're excited to be moving our programs forward at Leal Therapeutics!
Asa Abeliovich targets ALS, schizophrenia with new biotech startup Leal Therapeutics
https://endpts.com
-
We’re #hiring a new Director, Toxicology/Nonclinical! Apply today or share this post with your network.
-
We are #hiring to expand our Business Development and Operations team!